Profile data is unavailable for this security.
About the company
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
- Revenue in EUR (TTM)9.52m
- Net income in EUR-13.06m
- Incorporated2017
- Employees97.00
- LocationHeidelberg Pharma AGSchriesheimer Strasse 101LADENBURG 68526GermanyDEU
- Phone+49 620310090
- Fax+49 6 203100919
- Websitehttps://www.heidelberg-pharma.com/
Holder | Shares | % Held |
---|---|---|
Polar Capital LLPas of 31 May 2024 | 281.27k | 0.60% |
Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 30 Apr 2024 | 246.00k | 0.53% |
Financi�re Arbevel SAas of 30 Dec 2022 | 13.40k | 0.03% |
Gutmann Finanz Strategien AGas of 31 Mar 2024 | 3.40k | 0.01% |
Private Verm�gensVerwaltung AGas of 31 Mar 2024 | 0.00 | 0.00% |
State Board of Administration of Florida Retirement Systemas of 30 Jun 2023 | 0.00 | 0.00% |